TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00880672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dutasteride
Description: 5mg, oral, daily, 2-4 weeks
Study: NCT01614236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: Patients in one set (40 patients/sct) will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural
Description: patients will be randomized similarly but will undergo surgery under epidural analgesia
Study: NCT01918098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/naloxone prolonged release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/naloxone prolonged release tablets
Study: NCT01220648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib, interferon-alfa
Study: NCT01952834

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GoodBelly Probiotic
Description: GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
Study: NCT04056364

Intervention type: BIOLOGICAL
Intervention: sputum cytology
Description: Sputum cytology refers to the examination of sputum (mucus) under a microscope to look for abnormal or cancerous cells. Sputum, or phlegm, is the fluid that is secreted by cells in the lower respiratory tract such as the bronchi and the trachea. It differs from saliva, in that it contains cells that line the respiratory passages.

Intervention type: BIOLOGICAL
Intervention: sputum cytology
Description: Sputum cytology refers to the examination of sputum (mucus) under a microscope to look for abnormal or cancerous cells. Sputum, or phlegm, is the fluid that is secreted by cells in the lower respiratory tract such as the bronchi and the trachea. It differs from saliva, in that it contains cells that line the respiratory passages.

Intervention type: BIOLOGICAL
Intervention: sputum cytology
Description: Sputum cytology refers to the examination of sputum (mucus) under a microscope to look for abnormal or cancerous cells. Sputum, or phlegm, is the fluid that is secreted by cells in the lower respiratory tract such as the bronchi and the trachea. It differs from saliva, in that it contains cells that line the respiratory passages.
Study: NCT03615638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fall prevention program
Description: 12-week fall prevention program (including warm-up, cool-down, education, Tai Chi, and lower limb strengthening)
Study: NCT02530359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo equivalent
Description: Placebo equivalent per mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo equivalent
Description: Placebo equivalent per mouth
Study: NCT04468607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLYG8824A
Description: BLYG8824A will be administered at a flat dose independent of body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLYG8824A
Description: BLYG8824A will be administered at a flat dose independent of body weight.
Study: NCT00102544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EM Tracking
Description: Utilizing electromagnetic tracking technology as a fusion and navigation tool for minimally invasive interventional procedures.
Study: NCT02786056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung MRI examination
Description: Lung MRI examination is performed for approximately 30 min on a 3T machine (Achieva 3T, Philips) using UTE sequences, both during free breathing with image synchronisation using an echo-navigator, and during an end-inspiratory and end-expiratory pauses. In the 10 first subjects, the MR protocol is optimized in order to maximize MRI parenchymal signal intensity, signal-to-noise ratio and contrast-to-noise ratio. The final image acquisition parameters will be applied in the following 30 subjects in order to assess the outcomes of the study.
Study: NCT02423759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciprofloxacin
Description: 500mg ciprofloxacin twice daily starting the day before biopsy and continued for 3 days after

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin and gentamycine
Description: standard chemoprophylaxis plus gentamicin 160mg intramuscular once just before the biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: culture based chemoprophylaxis
Description: Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
Study: NCT03805269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAP block
Description: TAP block: local anesthetics infiltration at trans abdominis plane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: wound infiltration
Description: wound infiltration: local anesthetics infiltration at surgical incision
Study: NCT03756077

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT
Description: 0.05-0.06 mCi per kilogram bodyweight of 68Ga-PSMA, 0.1-0.15 mCi per kilogram bodyweight of 18F-FDG will be injected intravenously prior to imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT
Description: 0.05-0.06 mCi per kilogram bodyweight of 68Ga-PSMA, 0.1-0.15 mCi per kilogram bodyweight of 18F-FDG will be injected intravenously prior to imaging
Study: NCT01607242

Intervention type: OTHER
Intervention: Endoscopy of larynx
Description: Endoscopic Laryngeal mobility assessment

Intervention type: OTHER
Intervention: Voice Handicap Index
Description: Subjective Evaluation of Voice disorders

Intervention type: OTHER
Intervention: Swallowing Assesment
Description: Swallowing function questionnaire
Study: NCT02188108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wisconsin Stone-QOL survey
Description: Patients will complete a health-related quality of life survey at multiple time points at enrollment and at multiple time points thereafter.
Study: NCT03844880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy
Description: Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
Study: NCT03659500

Intervention type: DIAGNOSTIC_TEST
Intervention: Four-week routine bloodwork
Description: Routine hemodialysis bloodwork done every 4 weeks

Intervention type: DIAGNOSTIC_TEST
Intervention: Six-week routine bloodwork
Description: Routine hemodialysis bloodwork done every 6 weeks
Study: NCT01890369

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15g Mixed Essential Amino Acids
Description: Dissolved in 250ml water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15g Mixed Essential Amino Acids
Description: Dissolved in 250ml water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15g Mixed Essential Amino Acids
Description: Dissolved in 250ml water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15g Mixed Essential Amino Acids
Description: Dissolved in 250ml water.
Study: NCT04346888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161 Injection (680mg and 340 mg)
Description: HBM9161 Injection (680mg and 340mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo, HBM9161 Injection (340mg)
Study: NCT01890369

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3g Leucine
Description: Dissolved in 250ml water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15g Mixed Essential Amino Acid REFEED
Description: Dissolved in 250ml water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15g Mixed Essential Amino Acid REFEED
Description: Dissolved in 250ml water.
Study: NCT01581580

Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic Activa Tremor Control System
Description: Medtronic DBS Therapy delivers electrical stimulation to an area in the brain to help treat Parkinson's Disease, dystonia, and essential tremor.
Study: NCT01890369

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15g Mixed Essential Amino Acid REFEED
Description: Dissolved in 250ml water.
Study: NCT01823978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-201 vaccine plus AP1903
Description: The trial design consists of 3 cohorts of 6 patients each, receiving escalating doses of BPX-201 of 10 million (M), 20M and 40M cells, respectively. Dose escalation will occur according to a 3+3 design. Patients will receive administration of BPX-201 every other week for 6 cycles (1 cycle equals 2 weeks). Approximately 1.6 mL of BPX-201 will be administered as 8 intradermal injections (200μL each) at each treatment visit. On the day following each vaccination, a single 40 mg dose of the activating agent, AP1903, will be administered via intravenous (IV) infusion over 2 hours.
Study: NCT05164185

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Brief cycles of ischemia to a limb. A blood pressure cuff was placed around the right thigh and inflated to 200 mmHg for 4 cycles of 5 minutes.
Study: NCT01581580

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Deep Brain Stimulation
Description: standard of care DBS surgery for patients with Parkinson's Disease, dystonia, and essential tremor
Study: NCT05164185

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Brief cycles of ischemia to a limb. A blood pressure cuff was placed around the right thigh and inflated to 200 mmHg for 4 cycles of 5 minutes.
Study: NCT03883711

Intervention type: OTHER
Intervention: Database
Description: Create a database containing clinical characteristic, clinical presentation, flow indexes and treatment of consecutive incident patients with ACS or myocardial injury.
Study: NCT04118764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuronavigation-guided single-element focused ultrasound transducer
Description: Non-invasive focused ultrasound-induced blood-brain barrier opening will be attempted using a single-element transducer, guided with a neuronavigation system.
Study: NCT01778972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago home exercise programme
Description: Otago home exercise program was designed specifically to prevent falls. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.~The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus Otago
Description: This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
Study: NCT04118764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: Definity microbubbles (10 μl/kg) will be used in conjunction with the ultrasound transducer to temporarily open the blood brain barrier.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents
Description: MRI scans will be completed at baseline and immediately after the focused ultrasound treatment to confirm BBB opening and safety. A follow-up MRI will be performed three days after treatment to confirm BBB closure, only in the case of successful BBB opening.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: A follow-up PET scan will be performed three days after treatment to determine amyloid plaque load.
Study: NCT03338010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Description: Administered SC
Study: NCT01176383

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Respiragene test and risk score
Description: This 12 gene test used with other data (family history, age and spirometry result) to calculate lifetime risk of lung cancer in smokers who do not quit smoking. This intervention is expected to be a motivator to quit.
Study: NCT04118764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amyvid
Description: To be used during the PET scan to determine uptake of Amyvid within the treated area.
Study: NCT03582176

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Placebo
Description: One capsule by mouth twice per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen Fumarate 2mg
Description: 2 mg tablets (over-encapsulated into one capsule) by mouth twice per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen Fumarate 2mg
Description: 2 mg tablets (over-encapsulated into one capsule) by mouth twice per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen Fumarate 5mg
Description: 5 mg tablets (over-encapsulated into one capsule) by mouth twice per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen Fumarate 5mg
Description: 5 mg tablets (over-encapsulated into one capsule) by mouth twice per day
Study: NCT03404713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pathways to Health
Description: Manualized sessions will follow an acceptance based behavioral weight loss treatment approach, including guided goal-setting and self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks and relapse prevention. Daily food and physical activity are logged and monitored. Parents learn strategies to support and facilitate their child's weight management via family-based change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pathways to Health
Description: Manualized sessions will follow an acceptance based behavioral weight loss treatment approach, including guided goal-setting and self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks and relapse prevention. Daily food and physical activity are logged and monitored. Parents learn strategies to support and facilitate their child's weight management via family-based change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be4U
Description: This intervention is grounded in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), and Acceptance and Commitment Therapy (ACT). The core elements include regulating eating patterns, self-monitoring, developing openness to an acceptance perspective, fostering a willingness to accept distress, teaching defusion from distressing thoughts and feelings, practicing mindful awareness, fostering self-as-context, and directing patients towards clarifying and focusing on life values. Self-monitoring of eating behaviors and emotions are encouraged using a free app that facilitates electronic self-monitoring of eating patterns and symptoms. For participants who elect not to use this app, paper self-monitoring records are provided.
Study: NCT03801343

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrakos®
Description: Nutrakos® Amino Acid Food Supplement supplies a specific mixture of amino acids that has been proven to induce synthesis of collagen and elastin, the main proteins of derma structure in fibroblasts and keratocytes.
Study: NCT01446978

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis A vaccine
Description: 3 doses of hepatitis A vaccine, given at 0+1+6 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis A vaccine
Description: Two doses of hepatitis A vaccine given at day 0, one in each M deltoids. An additional dose will be given at 6 months later
Study: NCT02696460

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: N2O/O2 analgesia
Description: Analgesia for ulcer debridement procedure is provided by the inhalation of N2O/O2 gas premix.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: N2O/O2 analgesia
Description: Analgesia for ulcer debridement procedure is provided by the inhalation of N2O/O2 gas premix.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine/Prilocaine analgesia
Description: Analgesia for ulcer debridement procedure is provided by topically administered lidocaine/prilocaine cream.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine/Prilocaine analgesia
Description: Analgesia for ulcer debridement procedure is provided by topically administered lidocaine/prilocaine cream.
Study: NCT03306563

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sample collection
Description: Samples of blood, urine and saliva will be collected at up to five successive time points.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sample collection
Description: Samples of blood, urine and saliva will be collected at up to five successive time points.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sample collection
Description: Samples of blood, urine and saliva will be collected at up to five successive time points.
Study: NCT00958100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir emtricitabine raltegravir
Description: switch from current antiretroviral regimen to raltegravir with tenofovir/emtricitabine as backbone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine Abacavir Raltegravir
Description: Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir free
Description: Patients will receive raltegravir with tenofovir/emtricitabine; data will be added to those of Tenofovir Emtricitabine Raltegravir arm in a separate longitudinal analysis comparing data at baseline and at 48 weeks. In this separate analysis, data will not be compared to those obtained from the Lamivudine Abacavir Raltegravir arm. The number of patients in this arm is not pre-established.
Study: NCT04346888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161 Injection (340 mg)
Description: HBM9161 Injection (340 mg)
Study: NCT03414710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education booklet plus video plus brief counseling
Description: Participants in the intervention group will receive a health education booklet, watch a 10-minute video and receive counseling provided by the clinicians

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education booklet only
Description: Participants in the intervention group will only receive a health education booklet
Study: NCT00385801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02765373

Intervention type: DRUG
Intervention: Exemestane

Intervention type: DRUG
Intervention: Letrozole

Intervention type: DRUG
Intervention: Anastrozole
Study: NCT02163915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-137
Description: TAK-137 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-137
Description: TAK-137 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-137
Description: TAK-137 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-137
Description: TAK-137 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-137
Description: TAK-137 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-137 Placebo
Description: TAK-137 placebo-matching tablets
Study: NCT00208767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan was titrated to a target dose of 320 mg orally daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matched placebo pill will be given orally daily.
Study: NCT01393912

Intervention type: DRUG
Group type: OTHER
Intervention: Crenolanib
Description: Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Crenolanib
Description: Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy
Study: NCT05442463

Intervention type: DRUG
Intervention: Captopril Tablets
Description: Captorpril challenge to each participant

Intervention type: DRUG
Intervention: Captopril Tablets
Description: Captorpril challenge to each participant
Study: NCT03663218

Intervention type: RADIATION
Group type: OTHER
Intervention: Dose escalation
Description: This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.
Study: NCT01805921

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given intra-nasally (high dose)
Description: High dose = 5x10\^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given intra-nasally (high dose)
Description: High dose = 5x10\^10 vp
Study: NCT03685799

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathological revision
Description: Pathological revision
Study: NCT02939144

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquorice
Description: Liquorice ingestion will mimic the inherited condition of 'Apparent mineralocorticoid excess (AME)by showing the effects of the reduced activity of 11ßHSD-2 (which leads to an accumulation of cortisol which binds MR and hence has the effect of aldosterone).